Technical Analysis for KMDA - Kamada Ltd.

Grade Last Price % Change Price Change
grade C 5.6 -3.95% -0.23
KMDA closed down 3.95 percent on Monday, March 25, 2019, on 1.31 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical KMDA trend table...

Date Alert Name Type % Chg
Mar 25 Fell Below 50 DMA Bearish 0.00%
Mar 25 200 DMA Support Bullish 0.00%
Mar 25 Cup with Handle Other 0.00%
Mar 25 Lower Bollinger Band Walk Weakness 0.00%
Mar 25 Below Lower BB Weakness 0.00%
Mar 25 Down 3 Days in a Row Weakness 0.00%
Mar 25 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Cup with Handle Other -3.95%
Mar 22 Calm After Storm Range Contraction -3.95%
Mar 22 Lower Bollinger Band Touch Weakness -3.95%

Older signals for KMDA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Medicine Biopharmaceutical Alpha Cystic Fibrosis Anatomy Blood Cardiac Surgery Antitrypsin Deficiency Blood Products Coagulation System Bronchiectasis Coagulation Alpha 1 Antitrypsin Heparins Immune Thrombocytopenic Purpura
Is KMDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.45
52 Week Low 4.35
Average Volume 62,264
200-Day Moving Average 5.5319
50-Day Moving Average 5.661
20-Day Moving Average 5.9763
10-Day Moving Average 5.9095
Average True Range 0.202
ADX 27.96
+DI 19.2854
-DI 30.3435
Chandelier Exit (Long, 3 ATRs ) 5.824
Chandelier Exit (Short, 3 ATRs ) 6.136
Upper Bollinger Band 6.2614
Lower Bollinger Band 5.6912
Percent B (%b) -0.16
BandWidth 9.54102
MACD Line 0.0275
MACD Signal Line 0.0883
MACD Histogram -0.0608
Fundamentals Value
Market Cap 209.44 Million
Num Shares 37.4 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -112.00
Price-to-Sales 2.15
Price-to-Book 2.76
PEG Ratio 9.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.93
Resistance 3 (R3) 5.94 5.85 5.88
Resistance 2 (R2) 5.85 5.76 5.84 5.86
Resistance 1 (R1) 5.72 5.71 5.68 5.71 5.84
Pivot Point 5.63 5.63 5.60 5.62 5.63
Support 1 (S1) 5.50 5.54 5.46 5.49 5.36
Support 2 (S2) 5.41 5.49 5.40 5.34
Support 3 (S3) 5.28 5.41 5.33
Support 4 (S4) 5.27